Chapter 5 Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million cases in children younger than 5 years, with 10% requiring hospital admission and up to 199,000 dying of the disease. There is growing evidence that severe infantile RSV bronchiolitis, a condition characteris...

Full description

Saved in:
Bibliographic Details
Main Author: Jha, Akhilesh (auth)
Other Authors: Jarvis, Hannah (auth), Fraser, Clementine (auth), Openshaw, Peter (auth)
Format: Electronic Book Chapter
Language:English
Published: Sheffield European Respiratory Society 2016
Subjects:
Online Access:OAPEN Library: download the publication
OAPEN Library: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 oapen_2024_20_500_12657_47857
005 20210415
003 oapen
006 m o d
007 cr|mn|---annan
008 20210415s2016 xx |||||o ||| 0|eng d
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a MJC  |2 bicssc 
100 1 |a Jha, Akhilesh  |4 auth 
700 1 |a Jarvis, Hannah  |4 auth 
700 1 |a Fraser, Clementine  |4 auth 
700 1 |a Openshaw, Peter  |4 auth 
245 1 0 |a Chapter 5 Respiratory Syncytial Virus 
260 |a Sheffield  |b European Respiratory Society  |c 2016 
300 |a 1 electronic resource (38 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Respiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million cases in children younger than 5 years, with 10% requiring hospital admission and up to 199,000 dying of the disease. There is growing evidence that severe infantile RSV bronchiolitis, a condition characterised by an inflammatory reaction to the virus, is associated with later childhood wheeze in some vulnerable children; however, a direct causal relationship with asthma has not yet been established. It is also increasingly recognised as a cause of morbidity and mortality in those with underlying airway disease, immunocompromise and frail elderly persons. Novel molecular based diagnostic tools are becoming established but treatment largely remains supportive, with palivizumab being the only licensed agent currently available for passive prophylaxis of selected pre-term infants. Whilst effective treatments remain elusive, there is optimism about the testing of novel antiviral drugs and the development of vaccines that may induce long-lasting immunity without the risk of disease augmentation. 
536 |a Wellcome Trust 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by-nc/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by-nc/4.0/ 
546 |a English 
650 7 |a Diseases & disorders  |2 bicssc 
653 |a viral lung disease, RSV, paediatric infections, bronchiolitis, mucosal immunity 
773 1 0 |t SARS, MERS and other Viral Lung Infections  |7 nnaa  |o OAPEN Library UUID: 5cf1fb3c-d029-40f8-9de5-4f395f9e3256 
856 4 0 |a www.oapen.org  |u https://library.oapen.org/bitstream/id/ca2b7105-bcf4-4144-a41c-fd67c06341a2/Bookshelf_NBK442240.pdf  |7 0  |z OAPEN Library: download the publication 
856 4 0 |a www.oapen.org  |u https://library.oapen.org/handle/20.500.12657/47857  |7 0  |z OAPEN Library: description of the publication